(Q37125070)

18 August 2017

Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors (English)

1 reference

18 August 2017

0 references

1 reference

Sharyn D Baker

14

1 reference

ORCID Public Data File 2021

author name string

Antonio Jimeno

1

1 reference

18 August 2017

Michelle A Rudek

2

1 reference

18 August 2017

Peter Kulesza

3

1 reference

18 August 2017

Wen Wee Ma

4

1 reference

18 August 2017

Jenna Wheelhouse

5

1 reference

18 August 2017

Anna Howard

6

1 reference

18 August 2017

Yasmin Khan

7

1 reference

18 August 2017

Ming Zhao

8

1 reference

18 August 2017

Heather Jacene

9

1 reference

18 August 2017

Wells A Messersmith

10

1 reference

18 August 2017

Daniel Laheru

11

1 reference

18 August 2017

Ross C Donehower

12

1 reference

18 August 2017

Elizabeth Garrett-Mayer

13

1 reference

18 August 2017

Manuel Hidalgo

15

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 September 2008

1 reference

Journal of Clinical Oncology

18 August 2017

1 reference

18 August 2017

26

1 reference

18 August 2017

4172-4179

1 reference

18 August 2017

25

1 reference

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654371

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654371

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654371

TOR, a central controller of cell growth

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654371

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654371

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654371

4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654371

Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654371

Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654371

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654371

Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654371

Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to Cyclosporine-based immunosuppressive regimens in renal transplantation

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654371

Rapamycin's resurrection: a new way to target the cancer cell cycle

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654371

Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654371

Practical implementation of a modified continual reassessment method for dose-finding trials.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654371

TOR signalling and control of cell growth

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2654371

Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration

3 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18757332

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18757332

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JCO.2008.16.2347

1 reference

18 August 2017

1 reference

18 August 2017

1 reference